Business
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar management on Friday, November 12, 2021, at 12:00 p.m. EST during the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The call will be hosted by Nektar management and will include, SITC author and presenter, Dr. Mehmet Altan, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas Anderson Cancer Center and Dr. Alan Tan, Director of GU Medical Oncology and Assistant Professor in the Division of Hematology, Oncology and Cell Therapy at Rush University Medical Center.\n\n \n \n \n \n \n \n\n \nThe event will follow the publication of the NKTR-255 poster (Abstract #957) on Friday morning. SITC is being held in Washington, D.C. and virtually from November 10 to November 14, 2021.\nAnalyst Call:\nDate and Time: Friday, November 12, 2021, at 12:00 p.m. EST\nDial-in: 877-881-2183 (toll-free) or 970-315-0453 (enter access code 1769208)\nInvestors and analysts can also view slides and listen to the live audio webcast of the presentation at https://edge.media-server.com/mmc/p/aqdnveeb. The event will also be available for replay for two weeks on Nektar's website: www.nektar.com.\nDetails of the presentations at SITC are as follows:\nNektar Poster Presentations at SITC\nAbstract 957: \"NKTR-255 Plus Cetuximab in Patients with Solid Tumors: Interim Safety and Efficacy Results from the Phase 1b Dose Escalation Study,\" Altan, M., et al.\nPresenter: Dr. Mehmet Altan, MD Anderson Cancer Center ePoster and live poster will be available on Friday, November 12th, 2021, at 7:00 a.m. EST Poster reception: Friday, November 12, 2021, from 7:00 p.m. – 8:30 p.m. ESTAdditional Collaborator Presentations at SITC\nAbstract 59: \"Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial,\" Feils, AS., et al.\nePoster will be on display on the SITC 2021 virtual meeting platform on Friday, November 12, 2021, at 7:00 a.m. ESTAbstract 596: \"Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate ...